Maximilian Steinhardt
@MJSteinhardt
Followers
108
Following
8K
Media
11
Statuses
56
MD from Würzburg, Germany. Myeloma and Amyloidosis!
Joined September 2019
Excited to share new study out today on @JCO_ASCO where we leveraged #WGS to reclassify MGUS and SMM and define the concept of "malignant transformation" @MSKCancerCenter @LaStatale @MDAndersonNews @MoffittNews @SylvesterCancer @nyulangone @sangerinstitute @MayoClinic #mmsm 1/14
8
37
89
🧬 Proud to share: Publication in Blood Cancer Journal: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with EMD 👉CAR T-cell therapy and effective debulking resulted in higher EMD response rates, and prolonged PFS 👉
0
2
8
With the Acoramidis FDA approval, EU countries expect EMA approval in early 2025. With a hefty price tag (20k $/mo) and Tafamidis patent expiring late 2025, it will be interesting to see how prescriptions will turn out. Head-to-head comparisons will have to be done by academia!
Fantastic news. Attruby is here. And we have had excellent experience with its long-term use. Most unique about this announcement in my opinion - acoramidis/Attruby will be provided free for life for trial participants in the phase II and III. This is unprecedented at least in
3
0
5
Happy to finally see this published! Heartfelt congratulations to Mara for the hard work and big thanks to @RascheLeo for bringing the project forward!
EMD mimics the architectural complexity of solid tumors, marked by diverse microenvironments, multiclonality, and TNFRSF17 and GPRC5D levels. https://t.co/CeIT6zKAU3
#lymphoidneoplasia #immunobiologyandimmunotherapy #multiplemyeloma
1
4
5
I would not want my high risk SMM be treated if I had one. However, this will be discussed thoroughly and I am curious what the arguments will be.
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subc...
0
0
0
We are searching for a highly motivated PhD student (m/f/d) interested in developing novel CRISPR 2.0 gene editing technologies for CAR-T cell engineering and cancer immunotherapy @Uniklinikum_Wue & @Uni_WUE. Please RT 🙏.
5
145
291
I’m excited to share that my latest review article on AL amyloidosis is now published in the New England Journal of Medicine! @BU_Amyloidosis @BUMedicine @The_BMC Systemic Light Chain Amyloidosis | New England Journal of Medicine
nejm.org
Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, ...
25
49
198
#mdpijcm 💫Recommended Paper Safety and Tolerability of SGLT2 Inhibitors in Cardiac Amyloidosis—A Clinical Feasibility Study ( https://t.co/2CW6AHOpJY) ✍️by @MJSteinhardt et al. 🏢 @Uniklinikum_Wue @lunduniversity
#2024Article #OpenAccess #cardio #kidney
Should we use SGLT2 inhibitors in Amyloidosis? We found it is safe and effects are identical to the pivotal studies: https://t.co/V9WtoQr0xz
0
2
1
From scientific talks, inspiring atmosphere, clean preparations to silent disco @ #ISA2024, I can’t think of anything that could be done better. Thanks to @ADispenzieri, @MorieGertz, @MarthaGrogan1, Stefan Schönland @UniHeidelberg and the teams @MayoAmyloid and @ISA_Amyloidosis
0
0
6
Great experience with @VJHemOnc as always! Very informed, prepared and professional. If you missed #ISA2024 definitely watch their interviews.
We’re thrilled to have interviewed leading experts throughout #ISA2024! For exclusive interviews on the latest advances in #Amyloidosis, check out: 👉 https://t.co/fL3cQLjMW1
#HemOnc @ISA_Amyloidosis #ISA_2024
1
2
5
Should we use SGLT2 inhibitors in Amyloidosis? We found it is safe and effects are identical to the pivotal studies: https://t.co/V9WtoQr0xz
mdpi.com
Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve the prognosis of patients with heart failure. Amyloidosis constitutes an important...
0
1
3
Great start into 2024: Adding to CANOVA, real-world data on Venetoclax with and without t(11;14)! Thanks to all my colleagues https://t.co/PSXGjiu678
0
1
2
#ASH22 was an incredible experience for me. Working in hematology, you know there is a lot of work behind all the knowledge. But to actually see the thousands of scientists, each a specialist in their field, was humbling. Thanks @ASH_hematology !
0
0
5
Glad to find everything in place! Thank you @ASH_hematology for the free printing service and hanging the poster. Getting a poster around the world can be troublesome. #ASH22
0
1
10
This is gold for everyday decisions. FLC reference intervals (in mainly white population) without selection bias:
Our paper were we redefine the reference intervals for serum FLCs and FLC ratio in individuals with chronic kidney disease using the #iStopMM data has been published! Full paper here: https://t.co/igtZ2xZUUV
#mmsm #Nephrology Summary of the new reference intervals:
0
1
3
Thought-provoking slide from Prof. Palladini. ASCT soon second line in AL #Amyloidosis? We need more data to know when to recommend though.
0
1
2
Congratulations to my colleagues from @uniklinik_hd for a perfect #ISA2022 ! Going home with fresh ideas and new friends.
1
0
7
What a day at #ISA2022 with lots of input and ideas for my colleagues and me from @DZHI_Wuerzburg !
0
0
2